Grundy SM. Metabolic syndrome: Connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006; 47(6): 1093-100.
Mittermayer F, Caveney E, De Oliveira C, et al. Addressing unmet medical needs in type 2 diabetes: a narrative review of drugs under development. Curr Diabetes Rev 2015; 11: 17-31.
Huang ES. Appropriate application of evidence to the care of elderly patients with diabetes. Curr Diabetes Rev 2007; 3: 260-3.
Myers A. Editorial: Management of Diabetes in Unique Populations. Curr Diabetes Rev 2017; 13: 193-4.
American Diabetes Association. Older adults. Sec. 10. In Standards of Medical Care in Diabetes. Diabetes Care 2016; 39(Suppl. 1): S81.
Orlando V, Guerriero F, Putignano D, et al. Prescription patterns of antidiabetic treatment in the elderly. results from southern italy. Curr Diabetes Rev 2015; 12: 100-6.
Lipska KJ, Krumholz H, Soones T, Lee SJ. Polypharmacy in the aging patient: a review of glycemic control in older adults with type 2 diabetes. JAMA 2016; 315: 1034-45.
Ziegler D. Current concepts in the management of diabetic polyneuropathy. Curr Diabetes Rev 2011; 7: 208-20.
Grant RW, Devita NG, Singer DE, et al. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care 2003; 26: 1408-12.
Myers AK, Trivedi MH. Death by Insulin: Management of Self-Harm and Suicide in Diabetes Management. Curr Diabetes Rev 2017; 13: 251-62.
Pompili M, Forte A, Lester D, et al. Suicide risk in type 1 diabetes mellitus: A systematic review. Psychosom Res 2014; 76: 352-60.
Austin RP. Polypharmacy as a risk factor in the treatment of type 2 diabetes. Diabetes Spectr 2006; 19: 13-6.
van Bruggen R, Gorter K, Stolk RP, et al. Refill adherence and polypharmacy among patients with type 2 diabetes in general practice. Pharmacoepidemiol Drug Saf 2009; 18: 983-91.
Huang ES, Karter AJ, Danielson KK, et al. The association between the number of prescription medications and incident falls in a multi-ethnic population of adult type-2 diabetes patients: the diabetes and aging study. J Gen Intern Med 2010; 25: 141-6.
Dunn JD. Diabetes pharmacy management: balancing safety, cost, and outcomes. Am J Manag Care 2010; 16(7)(Suppl.): S201-6.
Moreira Bde S, Sampaio RF, Furtado SR, Dias RC, Kirkwood RN. The relationship between diabetes mellitus, geriatric syndromes, physical function, and gait: a review of the literature. Curr Diabetes Rev 2016; 12: 240-51.
Azuma K, Heilbronn LK, Albu JB, et al. Adipose tissue distribution in relation to insulin resistance in type two diabetes. Am J Physiol Endocrinol Metab 2007; 293: E435-42.
Erkelens DW. Insulin resistance syndrome and type 2 diabetes mellitus. Am J Cardiol 2001; 88(Suppl.): 38J-42J.
Hawkins M, Tonelli J, Kishore P, et al. Contribution of elevated free fatty acids to the lack of glucose effectiveness in type 2 diabetes. Diabetes 2003; 52: 2748-58.
Pi-Sunyer FX. Pathophysiology and long-term management of the metabolic syndrome. Obes Res 2004; 12(Suppl.): 174S-80S.
Avogaro A, Fadini GP, Gallo A, et al. Endothelial dysfunction in type two diabetes mellitus. Nutrition, Metabolism & Cardiovascular Diseases 2006; 16(Suppl.): S39-45.
Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology and management. JAMA 2002; 287: 2570-81.
Cheung BM. The hypertension-diabetes continuum. J Cardiovasc Pharmacol 2010; 55: 333-9.
Kalofoutis C, Piperi C, Kalofoutis A, et al. Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approaches. Exp Clin Cardiol 2007; 12: 17-28.
Tancredi M, Rosengren A, Svensson AM, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med 2015; 373: 1720-32.
Salvetti A, Brogi G, Di Legge V, et al. The inter-relationship between insulin resistance and hypertension. Drugs 1993; 46(Suppl. 2): 149-59.
Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004; 27: 1496-504.
Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type two diabetes and familial combined hyperlipidemia in coronary artery disease risk. J of Clin Endocrinol Metab 2004; 89: 2601-7.
Gresele P, Guglielmini G, De Angelis M, et al. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol 2003; 41: 1013-20.
Feher MD. Diabetes: Preventing coronary heart disease in a high risk group. Heart 2004; 90(Suppl. IV): iv18-21.
Roper NA, Bilous RW, Kelly WF, et al. South tees diabetes mortality study. cause-specific mortality in a population with diabetes: south tees diabetes mortality study. Diabetes Care 2002; 25: 43-8.
Wright E Jr, Scism-Bacon JL, Glass LC. Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia. Int J Clin Pract 2006; 60: 308-14.
Locatelli F, Canaud B, Eckardt KU, et al. Oxidative stress in endstage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003; 18: 1272-80.
Keane WF, Brenner BM, de Zeeuw D, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and neph- ropathy: the RENAAL study. Kidney Int 2003; 63: 1499-507.
Njajou OT, Kanaya AM, Holvoet P, et al. Association between oxidized LDL, obesity and type 2 diabetes in a population based cohort, the health aging and body composition study. Diabetes Metab Res Rev 2009; 25: 733-9.
Guldiken B, Guldiken S, Turgut B, et al. The roles of oxidized low- density lipoprotein and interleukin-6 levels in acute atherothrom- botic and lacunar ischemic stroke. Angiology 2008; 59: 224-9.
Boudjeltia KZ, Legssyer I, Antwerpen PV, et al. Triggering of inflammatory response by myeloperoxidase-oxidized LDL. Biochem Cell Biol 2006; 84: 805-12.
Devaraj S, Tang R, Adams-Huet B, Harris A, et al. Effect of high- dose α- tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease. Am J Clin Nutr 2007; 86: 1392-8.
Hulthe J, Wikstrand J, Fagerberg B. Relationship between c- reactive protein and intima-media thickness in the carotid and femoral arteries and to antibodies against oxidized low-density lipoprotein in healthy men: the atherosclerosis and insulin resistance (AIR) study. Clin Sci 2001; 100: 371-8.
Lodh M, Goswami B, Parida A, et al. Assessment of serum leptin, pregnancy- associated plasma protein A and CRP levels as indicators of plaque vulnerability in patients with acute coronary syndrome. Cardiovasc J Afr 2012; 23: 330-5.
Nishi K, Itabe H, Uno M, et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol 2002; 22: 1649-54.
Niccoli G, Mongiardo R, Lanza GA, et al. The complex link between oxidised low-density lipoprotein and unstable angina. J Cardiovasc Med (Hagerstown) 2007; 8: 387-91.
Ragino YI, Chernjavski AM, Polonskaya YV, et al. Oxidation and endothelial dysfunction biomarkers of atherosclerotic plaque instability: Studies of the vascular wall and blood. Bull Exp Biol Med 2012; 153: 331-5.
Kobayashi S, Inoue N, Ohashi Y, et al. Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of c-reactive protein. Arteriosclersclerosis Thrombosis and Vascular Biology 2003; 23: 1398-404.
Calabrò P, Golia E, Yeh ET. CRP and the risk of atherosclerotic events. Semin Immunopathol 2009; 31: 79-94.
Koenig W, Sund M, Fröhlich M, et al. C-Reactive protein, a sensi- tive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease. Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-42.
Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006; 17: 4-12.
Prasad K. C-reactive protein and cardiovascular diseases. International Journal of Angiology 2003; 12: 1-12.
Pradhan AD, Ridker PM. Do atherosclerosis and type two diabetes share a common inflammatory basis. Eur Heart J 2002; 23: 831-4.
Schwedler SB, Filep JG, Galle J, et al. C-reactive protein: A family of proteins to regulate cardiovascular function. American Journal of Kidney Diseases 2006; 47: 212-22.
Dandona P, Aljada A, Chaudhuri A, et al. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111: 1448-54.
Setchell KDR, Brown NM, Zimmer-Nechemias L, et al. Metabolism of secoisolariciresinol-diglycoside the dietary precursor to the intestinally derived lignan enterolactone in humans. Food & Funct 2014; 5: 491-501.
Nurmi T, Mursu J, Peñalvo JL, et al. Dietary intake and urinary excretion of lignans in Finnish men. Br J Nutr 2010; 103: 677-85.
Bannwart C, Adlercreutz H, Wähälä K, et al. Detection and identi- fication of the plant lignans lariciresinol, isolariciresinol and secoisolariciresinol in human urine. Clin Chim Acta 1989; 180: 293-301.
Milder IE, Feskens EJ, Arts IC, et al. Intake of the plant lignans secoisolariciresinol, matairesinol, lariciresinol, and pinoresinol in Dutch men and women. J Nutr 2005; 135: 1202-7.
Frankenfeld CL. Cardiometabolic risk factors are associated with high urinary enterolactone concentration, independent of urinary enterodiol concentration and dietary fiber intake in adults. J Nutr 2014; 144: 1445-53.
de Kleijn MMJ, van der Schouw YT, Wilson PWF, et al. Dietary intake of phytoestrogens is associated with a favorable metabolic cardiovascular risk profile in postmenopausal US women: The Framingham study. J Nutr 2002; 132: 276-82.
Barre DE, Mizier-Barre KA, Stelmach E, et al. Flaxseed lignan complex administration in older human type 2 diabetes patients manages central obesity and prothrombosis - an invitation to further investigation into polypharmacy reduction. J Nutr Metab 2012; (585170): 1-7.
Meagher LP, Beecher GR, Flanagan VP, et al. Isolation and characterization of the lignans, isolariciresinol and pinoresinol, in flaxseed meal. J Agric Food Chem 1999; 47: 3173-80.
Thompson LU, Boucher BA, Liu Z, et al. Phytoestrogen content of foods consumed in Canada, including isoflavones, lignans, and coumestan. Nutr Cancer 2006; 54: 184-201.
Hu Y, Song Y, Franke AA, et al. A prospective investigation of the association between urinary excretion of dietary lignan metabolites and weight change in US Women. Am J Epidemiol 2015; 182: 503-11.
Morisset AS, Lemieux S, Veilleux A, et al. Impact of a lignan-rich diet on adiposity and insulin sensitivity in post-menopausal women. Br J Nutr 2009; 102: 195-200.
Kang J, Park J, Kim HL, et al. Secoisolariciresinol diglucoside inhibits adipogenesis through the AMPK pathway. Eur J Pharmacol 2018; 820: 235-44.
Snijder MB, Dekker JM, Visser M, et al. Associations of hip and thigh circumferences independent of waist circumference with the incidence of type 2 diabetes: The Hoorn Study. Am J Clin Nutr 2003; 77: 1192-7.
Zhang W, Wang X, Liu Y, et al. Dietary flaxseed lignan extract lowers plasma cholesterol and glucose concentrations in hypercho- lesterolaemic subjects. Br J Nutr 2008; 99: 1301-9.
Hano C, Renouard S, Molinié R, et al. Flaxseed (Linum usitatis- simum L.) extract as well as (+)-secoisolariciresinol diglucoside and its mammalian derivatives are potent inhibitors of α-amylase activity. Bioorg Med Chem Lett 2013; 23: 3007-12.
Wikul A, Damsud T, Kataoka K, et al. (+)-Pinoresinol is a putative hypoglycemic agent in defatted sesame (Sesamum indicum) seeds though inhibiting α-glucosidase. Bioorg Med Chem Lett 2012; 22: 5215-7.
Rasouli H, Hosseini-Ghazvini SM, Adibi H, Khodarahmi R. Differential α-amylase/α-glucosidase inhibitory activities of plant- derived phenolic compounds: a virtual screening perspective for the treatment of obesity and diabetes. Food Funct 2017; 8: 1942-54.
Zhou F, Furuhashi K, Son MJ, et al. Antidiabetic effect of enterolactone in cultured muscle cells and in type 2 diabetic model db/db mice. Cytotechnology 2016; 69: 493-502.
Prasad K. Suppression of phosphoenolpyruvate carboxykinase gene expression by secoisolariciresinol diglucoside (SDG), a new an- tidiabetic agent. Int J Angiol 2002; 11: 107-9.
Huang SL, Yu RT, Gong J, et al. Arctigenin, a natural compound, activates AMP-activated protein kinase via inhibition of mitochon- dria complex I and ameliorates metabolic disorders in ob/ob mice. Diabetologia 2012; 55: 1469-81.
Sun Y, Zang Z, Zhong L, et al. Identification of adiponectin recep- tor agonist utilizing a fluorescence polarization based high throughput assay. PLoS One 2013; 8(5)e63354
Yang S, Na MK, Jang JP, et al. Inhibition of protein tyrosine phos- phatase 1B by lignans from Myristica fragrans. Phytother Res 2006; 20: 680-2.
Lee A, Choi KM, Jung WB, et al. Enhancement of glucose uptake by meso-dihydroguaiaretic acid through GLUT4 up- regulation in 3T3-L1 adipocytes. Molecules 2017; 22(9)E1423
Mohammad Shahi M, Zakerzadeh M, Zakerkish M, et al. Effect of sesamin supplementation on glycemic status, inflammatory mark- ers, and adiponectin levels in patients with type 2 diabetes mellitus. J Diet Suppl 2017; 22: 65-75.
Badole SL, Zanwar A, Bodhankar SL. Antihyperglycemic potential of secoisolaricinol diglucoside in bioactive food as dietary interventions for diabetes. Elsevier 2013; pp. 53-7.
Hallund J, Tetens I, Bügel S, et al. Daily consumption for six weeks of a lignan complex isolated from flaxseed does not affect endothelial function in healthy postmenopausal women. J Nutr 2006; 136: 2314-8.
Kreijkamp-Kaspers S, Kok L, Bots ML, et al. Dietary phytoestrogens and vascular function in postmenopausal women: a crosssectional study. J Hypertens 2004; 22: 1381-8.
Cornish SM, Chilibeck PD, Paus-Jennsen L, et al. A randomized controlled trial of the effects of flaxseed lignan complex on metabolic syndrome composite score and bone mineral in older adults. Appl Physiol Nutr Metab 2009; 34: 89-.
Kong X, Yang JR, Guo LQ, et al. Sesamin improves endothelial dysfunction in renovascular hypertensive rats fed with a high-fat, high-sucrose diet. Eur J Pharmacol 2009; 620: 84-9.
van der Schouw YT, Pijpe A, Lebrun CE, et al. Higher usual die- tary intake of phytoestrogens is associated with lower aortic stiffness in postmenopausal women. Arterioscler Thromb Vasc Biol 2002; 22: 1316-22.
Fukumitsu S, Aida K, Shimizu H, et al. Flaxseed lignan lowers blood cholesterol and decreases liver disease risk factors in moderately hypercholesterolemic men. Nutr Res 2010; 30: 441-6.
Kreijkamp-Kaspers S, Kok L, Bots ML, et al. Dietary phytoestro- gens and plasma lipids in Dutch postmenopausal women; a crosssectional study. Atherosclerosis 2005; 178: 95-100.
Adlercreutz H. Lignans and human health. Crit Rev Clin Lab Sci 2007; 44: 483-525.
Ide T, Ashakumary L, Takahashi Y, et al. Sesamin, a sesame lig- nan, decreases fatty acid synthesis in rat liver accompanying the down-regulation of sterol regulatory element binding protein-1. Biochim Biophys Acta 2001; 1534: 1-13.
Hirata F, Fujita K, Ishikura Y, et al. Hypocholesterolemic effect of sesame lignan in humans. Atherosclerosis 1996; 122: 135-6.
Hong L, Yi W, Liangliang C, et al. Hypoglycaemic and hypolipidaemic activities of sesamin from sesame meal and its ability to ameliorate insulin resistance in KK-Ay mice. J Sci Food Agric 2013; 93: 1833-8.
Peñalvo JL, López-Romero P. Urinary enterolignan concentrations are positively associated with serum HDL cholesterol and negatively associated with serum triglycerides in U.S. adults. J Nutr 2012; 142: 751-6.
Clark WF, Muir AD, Westcott ND, et al. A novel treatment for lupus nephritis: lignan precursor derived from flax. Lupus 2000; 9: 429-36.
Cox CP, Wood KL. Selective antagonism of platelet-activating factor (PAF)- induced aggregation and secretion of washed rabbit platelets by CV-3988, L-652731, triazolam and alprazolam. Thromb Res 1987; 47: 249-57.
Freedman JE. Oxidative stress and platelets. Arterioscler Thromb Vasc Biol 2008; 28(3): s11-6.
Moree SS, Rajesha J. Investigation of in vitro and in vivo antioxi- dant potential of secoisolariciresinol diglucoside. Mol Cell Biochem 2013; 373: 179-87.
Hu C, Yuan YV, Kitts DD. Antioxidant activities of the flaxseed lignan secoisolariciresinol diglucoside, its aglycone secoisolarici- resinol and the mammalian lignans enterodiol and enterolactone in vitro. Food Chem Toxicol 2007; 45: 2219-27.
Frank J, Eliasson C, Leroy-Nivard D, et al. Dietary secoisolariciresinol diglucoside and its oligomers with 3-hydroxy-3-methyl glutaric acid decrease vitamin E levels in rats. Br J Nutr 2004; 92: 169-76.
Vanharanta M, Voutilainen S, Nurmi T, et al. Association between low serum enterolactone and increased plasma F2-isoprostanes, a measure of lipid peroxidation. Atherosclerosis 2002; 160: 465-9.
Salonen JT, Nyyssönen K, Salonen R, et al. Antioxidant Supple- mentation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. J Intern Med 2000; 248: 377-86.
Prasad K. Antioxidant activity of secoisolariciresinol diglucoside- derived metabolites, secoisolariciresinol, enterodiol, and enterolactone. Int J Angiol 2000; 9: 220-5.
Hosseinian FS, Muir AD, Westcott ND, et al. Antioxidant capacity of flaxseed lignans in two model systems. J Am Oil Chemists’. Soc 2006; 83: 835-40.
Mukker JK, Michel D, Muir AD, Krol ES, Alcorn J. Permeability and conjugative metabolism of flaxseed lignans by Caco-2 human intestinal cells. J Nat Prod 2014; 77: 29-34.
Kuijsten A, Arts IC, Vree TB, et al. Pharmacokinetics of enterolignans in healthy men and women consuming a single dose of secoisolariciresinol diglucoside. J Nutr 2005; 135: 795-801.
Kitts DD, Yuan YV, Wijewickreme AN, et al. Antioxidant activity of the flaxseed lignan secoisolariciresinol diglycoside and its mammalian lignan metabolites enterodiol and enterolactone. Mol Cell Biochem 1999; 202: 91-100.
Almario RU, Karakas SE. Lignan content of the flaxseed influences its biological effects in healthy men and women. J Am Coll Nutr 2013; 32: 194-9.
Niemeyer HB, Metzler M. Differences in the antioxidant activity of plant and mammalian lignans. J Food Eng 2003; 56: 255-6.
Song CW, Wang SM, Zhou LL, et al. Isolation and identification of compounds responsible for antioxidant capacity of Euryale ferox seeds. J Agric Food Chem 2011; 59: 1199-204.
Prasad K. Secoisolariciresinol diglucoside from flaxseed delays the development of type two diabetes in Zucker rat. J Clin Lab Medic 2001; 138: 32-9.
Prasad K. Reduction of serum cholesterol and hypercholes- terolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Circulation 1999; 99: 1355-62.
Prasad K. Regression of hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Atherosclerosis 2008; 197: 34-42.
Nasermoaddeli A, Sekine M, Kagamimori S. Gender differences in associations of c-reactive protein with atherosclerotic risk factors and psychosocial characteristics in Japanese civil servants. Psychosom Med 2006; 68: 58-63.
Pan A, Demark-Wahnefried W, Ye X, et al. Effects of a flaxseed- derived lignan supplement on C-reactive protein, IL-6 and retinol- binding protein 4 in type 2 diabetic patients. Br J Nutr 2009; 101: 1145-9.
Pellegrini N, Valtueña S, Ardigò D, et al. Intake of the plant lignans matairesinol, secoisolariciresinol, pinoresinol, and lariciresinol in relation to vascular inflammation and endothelial dysfunction in middle age-elderly men and post- menopausal women living in Northern Italy. Nutr Metab Cardiovasc Dis 2010; 20: 64-71.
Spilioti E, Holmbom B, Papavassiliou AG, et al. Lignans 7- hydroxymatairesinol and 7-hydroxymatairesinol 2 exhibit anti- inflammatory activity in human aortic endothelial cells. Mol Nutr Food Res 2014; 58: 749-59.
Hallund J, Tetens I, Bügel S, et al. The effect of a lignan complex isolated from flaxseed on inflammation markers in healthy post- menopausal women. Nutr Metab Cardiovasc Dis 2007; 18: 497-502.
Hallund J, Ravn-Haren G, Bugel S, et al. A lignan complex isolated from flaxseed does not affect plasma lipid concentrations or anti- oxidant capacity in healthy postmenopausal women. The J Nutr 2006; 136: 112-6.